Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.
pharmaphorum3d
Novartis' LEE011 on fast track to challenge Ibrance
Novartis’ challenge to Pfizer’s blockbuster breast cancer drug, Ibrance, is building momentum, after the US regulator granted it a fast review. The US Food and Drug Administration granted the ...
Pharmaceutical Technology6d
Ibrance by Pfizer for Non-Small Cell Lung Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
pharmaphorum10d
Ibrance trial failure dashes Pfizer’s growth hopes for the drug
Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...
STAT24d
Pfizer’s blockbuster Ibrance slows tumor progression in another type of breast cancer
Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access to the medicine, potentially expanding its use. Ibrance, which generates ...
Big Pharma just hiked prices for more than 250 drugs
Pharmaceutical companies are raising the price of over 250 brand drugs this year. Nearly all the price increases are under 10 ...
Pharmaceutical Technology6d
Ibrance by Pfizer for Metastatic Brain Tumor: Likelihood of Approval
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase II drugs for Metastatic Brain Tumor have a 20% phase transition ...
Drugmakers to raise US prices on over 250 medicines starting Jan. 1
The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.
Benzinga.com24d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer's PATINA trial shows IBRANCE boosts progression-free survival in HR+/HER2+ metastatic breast cancer by over 15 months. Median PFS reached 44.3 months with IBRANCE plus standard anti-HER2 ...
Nasdaq24d
Pfizer's Ibrance, Combined With Standard Care, Boosts PFS In HR+, HER2+ Metastatic Breast Cancer
(RTTNews) - Pfizer Inc. (PFE), on Thursday, announced positive results from the Phase 3 PATINA trial, evaluating the addition of IBRANCE for treating metastatic breast cancer. The trial ...
Yahoo Finance23d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
Yahoo Finance24d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...